At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 330 enrolled
Drug / intervention
CBP-201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Multi-center, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of CBP-201 in Chinese Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating CBP-201 and Placebo for Moderate-to-severe Atopic Dermatitis. Completed, enrolled 330 participants across 48 sites.
Detailed Summary
This study will evaluate the efficacy and safety of CBP-201 in Chinese subjects with moderate to severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate-to-severe Atopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartAug 2021
Primary CompletionDec 2022
Study CompletionSep 2023
TodayJul 2026
First PostedAug 23, 2021
Enrollment StartAug 31, 2021
Primary CompletionDec 1, 2022
Study CompletionSep 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.9 years ago
Interventions
CBP-201drug
CBP-201 subcutaneous(SC) injection.
Placebodrug
subcutaneous(SC) injection